Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia
about
Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment optionsPharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature reviewA novel balanced chromosomal translocation found in subjects with schizophrenia and schizotypal personality disorder: altered l-serine level associated with disruption of PSAT1 gene expressionCircuit-based framework for understanding neurotransmitter and risk gene interactions in schizophreniaMeta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophreniaA randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophreniaGlutamate receptor ion channels: structure, regulation, and functionGlycine transport inhibitors for the treatment of schizophreniaMolecular targets for treating cognitive dysfunction in schizophrenia.Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia.Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex.NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease.Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update.Effects of sarcosine and N, N-dimethylglycine on NMDA receptor-mediated excitatory field potentials.Overview of glutamatergic neurotransmission in the nervous system.Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.D-serine and schizophrenia: an update.Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments.Targeting of NMDA receptors in new treatments for schizophrenia.Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine.Drug repurposing and emerging adjunctive treatments for schizophrenia.Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine.Beyond dopamine: glutamate as a target for future antipsychotics.Effects of (-)-stepholidine on NMDA receptors: comparison with haloperidol and clozapine.Two grams of sarcosine in schizophrenia - is it too much? A potential role of glutamate-serotonin interaction.Natural Medicines for Psychotic Disorders: A Systematic Review.Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects.Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.Multidimensional Connectomics and Treatment-Resistant Schizophrenia: Linking Phenotypic Circuits to Targeted TherapeuticsUncoupling DISC1 × D2R Protein-Protein Interactions Facilitates Latent Inhibition in Disc1-L100P Animal Model of Schizophrenia and Enhances Synaptic Plasticity via D2 Receptors
P2860
Q22241447-7D7FE320-C578-4BA3-B427-D41541503050Q24598636-EB43E901-C035-429F-97E6-923249DE5AB6Q24607731-67D558CD-721D-4285-BBB1-944F47BD9D9AQ24646206-5FB344FC-F8A9-48B3-9C69-C2D8C28B5E7BQ28248687-02A8E1DF-D456-45D2-A205-F622651EBF4AQ28263502-3824DDB0-6404-4CC4-8A96-17191C64010CQ28290774-96DAE230-08C1-424B-A43E-938B686EDAF7Q30477522-5F6415AF-B23D-418C-972C-888C6129CD12Q30491310-84E94EF8-34D5-454B-8D96-495E9173C2ABQ34230984-9F39BA91-9EDD-49D2-B112-87197FE9D1B3Q34274859-9C77F49F-0C62-4572-A289-C7CE35BD7C00Q34330678-FBF8874C-8C06-465E-8F74-14ED4F9744CBQ34381226-1491C4B4-4879-4AC7-B12A-130575165B7EQ35958805-370CC6D5-BFE5-4F2E-ABFB-73421B9AB267Q36247426-75443183-147C-4322-80C7-0D21F5EAECC9Q36310524-3C2C87F5-0E15-4ED7-A81F-8BD595AFFFE7Q36886717-A509C177-E112-4DFF-94BF-7822DD167EB5Q37358661-25C3813A-6530-4C64-B887-FBAC05963BA0Q37621271-E19E424B-BD80-422C-9FAE-22ACABA92920Q37673343-EE5CC683-03D4-4FD4-BE5F-AE504ED7FFEBQ37926162-7A59F6DD-6EBF-40A3-B6B0-A02B74493E10Q37954123-B2CC9A8A-4AD6-4C2E-87E9-4C6CC7714E70Q37979291-33BF431C-41DD-4709-9CC9-C4D49105A96FQ38031285-F71D2695-550A-4FF5-8C4A-385089A9FE44Q38151703-F3D2C45E-A09E-4377-B4D8-4C399DCB0C41Q38223276-C9F4076C-5D06-4DAA-B4D0-5697F351F8CAQ38256894-13DB4A0D-7B89-440A-8BDB-4EADBD893E23Q38417631-EA0C02E6-EA6E-441C-876F-81FEF5E9B1A6Q38917991-FF51C33C-2F5B-4403-A527-85C8BFC145F0Q39580232-9975D22C-2F52-4375-81CE-BC5FB2AAC605Q40116074-D118F3D3-C40C-4F8A-BADB-346CBD545786Q41945244-B3C54335-7B8F-4C7C-9906-D556AA344544Q49363880-88B37D4F-20B2-4435-9A97-0CFB1E9CA462Q50533040-D9480DAD-F9BA-463A-9B97-CC70B2C8B9D1Q50750840-8366280B-ED9F-440C-9973-A0475E8B0116Q58698014-38DFC833-8054-44A0-9253-5A10167D5B28Q58758781-E9726050-CD76-4ED7-97C8-B10FB805505B
P2860
Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Glycine transporter I inhibito ...... the treatment of schizophrenia
@ast
Glycine transporter I inhibito ...... the treatment of schizophrenia
@en
Glycine transporter I inhibito ...... the treatment of schizophrenia
@nl
type
label
Glycine transporter I inhibito ...... the treatment of schizophrenia
@ast
Glycine transporter I inhibito ...... the treatment of schizophrenia
@en
Glycine transporter I inhibito ...... the treatment of schizophrenia
@nl
prefLabel
Glycine transporter I inhibito ...... the treatment of schizophrenia
@ast
Glycine transporter I inhibito ...... the treatment of schizophrenia
@en
Glycine transporter I inhibito ...... the treatment of schizophrenia
@nl
P2093
P1476
Glycine transporter I inhibito ...... the treatment of schizophrenia
@en
P2093
Chieh-Liang Huang
Guochuan Tsai
Hsien-Yuan Lane
Pao-Yen Lin
Po-Wei Chen
Yi-Ching Liu
Yue-Cune Chang
P356
10.1016/J.BIOPSYCH.2006.04.005
P407
P577
2006-09-15T00:00:00Z